drugset / Trial / NCT00139867

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

NCT00139867 ↗

Phase 3 Completed UCB Pharma
RandomizedCrossoverOpen-label

Summary

The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.

Timeline

Start
2004-01
Primary completion
2004-05
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject carbidopa/levodopa Unknown — —

Indications